Drugmakers Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large late-stage trial involving high-risk melanoma patients.
–––
Subscribe to ABC News on YouTube: https://abcnews.visitlink.me/59aJ1G
ABC News is your daily source of breaking national and world news, exclusive interviews and 24/7 live streaming coverage. https://abcnews.com
Download the ABC News app for the latest headlines and alerts: https://abcnews.com/devices
Connect with ABC News on social media:
Facebook: https://www.facebook.com/ABCNews
Instagram: https://www.instagram.com/abcnews
TikTok: https://www.tiktok.com/@abcnews
X: https://twitter.com/ABC
Threads: https://www.threads.net/@abcnews
WhatsApp: https://whatsapp.com/channel/0029VajTNakKWEKkXoAPIR11
LinkedIn: https://www.linkedin.com/company/abcnews
Merck, Moderna melanoma vaccine succeeds
- Merck, Moderna claim 'promising' skin cancer vaccine results in key trial IOL —
- Merck, Moderna Melanoma Vaccine Study Succeeds Bloomberg —
- Merck, Moderna claim encouraging melanoma vaccine trial results South China Morning Post —
- Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning The New York Times —
- Merck, Moderna Stocks Soar After Melanoma Trial Success 📹 Bloomberg — · 2min
Personalized mRNA-based cancer vaccine shows promise
ABC News
— — 2min